Month: January 2022

SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in pharmaceutical films, today announced that patient dosing has resumed in the ongoing Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) under a previously amended protocol using higher doses of Montelukast VersaFilm®. “Resumption of patient dosing after a COVID-related interruption of the study of over one year is a significant milestone for this novel drug repurposing program, and we look forward to the BUENA trial producing valuable data that will provide more complete insight into the safety, feasibility, tolerability and efficacy of Montelukast VersaFilm® in patients with mild to moderate AD,” commented Dr. Horst Zerbe, IntelGenx’s CEO. “A significant...

THE WOODLANDS, Texas,, Jan. 20, 2022 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN) (“Conn’s” or the “Company”), a specialty retailer of furniture and mattresses, home appliances, consumer electronics and home office products, and provider of consumer credit, today announced that members of its senior leadership team will present details of the Company’s enhanced strategic growth plan and financial and operating goals at an Investor Day, which is being webcast today at 8:00 am CST. Conn’s is well-positioned to drive profitable growth and create sustained value for shareholders by strengthening its core business, enhancing its credit business and accelerating eCommerce growth. “I believe Conn’s is a stronger company today than at any other time in our 132-year history and I am excited by the opportunities we have to leverage our...

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide an update from the Company’s ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell...

The continuation patent application seeks to expand the protection of multi-dimensional integrated circuits architecture and semiconductor wafers mounted on the multi-dimensional planes SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”), filed a continuation patent application for its 3D, multiplanar, integrated circuits (IC) design and manufacturing technology. The original invention design presents a new way to design and manufacture larger size ICs to fit advanced analog, digital and mixed type ICs on a silicon wafer. The goal of these methods is to enable advanced microchip’s design and manufacturing within less space which can be a significant factor particularly for memories, CPU, GPU, AI chips and more. The company’s 3D microchip patent was filed on March 5,...

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information The conference call can be accessed live over the phone for U.S. callers by dialing (833) 519-1253 or for international callers by dialing +1 (914) 800-3826. The passcode to access the conference call is 6819125. A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days. About...

Monarch has received the final assays from its 2021 surface drilling program, which include high-grade intersections of 99.7 g/t Au over 0.6 m, 33.1 g/t Au over 0.5 m, 29.9 g/t Au over 0.7 m and 28.0 g/t Au over 0.6 m.These positive surface drilling results continue to define reserves and potentially mineable stopes near surface in the area of the W and 350 zones. These potential stope areas are located near surface, easily accessible from a surface ramp 350 metres from the main Beaufor shaft.This marks the completion of Monarch’s initially planned 42,500-metre Beaufor exploration drill program, which was successful at testing exploration targets defined by high-grade intersections and resource blocks near current existing underground development, both from surface and underground.Exploration and development drilling is continuing...

To NASDAQ Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 20 January 2022Company Announcement number 6/2022 Fixing of interest rate and refinancing triggersRealkredit Danmark hereby publishes interest rate and refinancing triggers. The interest rate and refinancing triggers are set out in the appendix to this announcement and is available on www.rd.dk/investor.   The Executive Board   Any additional questions should be addressed to Chief Analyst Hella Gebhardt Rønnebæk, phone +45 45 13 20 68.AttachmentsNr. 6_Fastsaettelse af triggerrenter_ukBilag til selskabsmeddelelse nr. 6-2022_uk

ORION CORPORATION PRESS RELEASE 20 January 2022 at 14.30 EET          Orion publishes Financial Statement Release for 2021 on Thursday 10 February 2022 Orion will publish Financial Statement Release for 2021 on Thursday, 10 February 2022 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media will be held on Thursday, 10 February 2022 at 13.30 EET. The event will be held only online and by conference call. A link to the live webcast will be available on Orion’s website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland:...